Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load

Overview

Journal Transl Oncol

Specialty Oncology

Date 2013 Jun 5

PMID 23730412

Citations 77

Authors

Florent Mouliere

Safia El Messaoudi

Celine Gongora

Anne-Sophie Guedj

Bruno Robert

Maguy Del Rio

Franck Molina

Pierre-Jean Lamy

Evelyne Lopez-Crapez

Muriel Mathonnet

Marc Ychou

Denis Pezet

Alain R Thierry

Affiliations

Soon will be listed here.

Abstract

We used a novel method based on allele-specific quantitative polymerase chain reaction (Intplex) for the analysis of circulating cell.free DNA (ccfDNA) to compare total ccfDNA and KRAS- or BRAF-mutated ccfDNA concentrations in blood samples from mice xenografted with the human SW620 colorectal cancer (CRC) cell line and from patients with CRC. Intplex enables single-copy detection of variant alleles down to a sensitivity of ≥0.005 mutant to wild-type ratio. The proportion of mutant allele corresponding to the percentage of tumor-derived ccfDNA was elevated in xenografted mice with KRAS homozygous mutation and varied highly from 0.13% to 68.7% in samples from mutation-positive CRC patients (n = 38). Mutant ccfDNA alleles were quantified in the plasma of every patient at stages II/III and IV with a mean of 8.4% (median, 8.4%) and 21.8% (median, 12.4%), respectively. Twelve of 38 (31.6%) and 5 of 38 (13.2%) samples showed a mutation load higher than 25%and 50%, respectively. This suggests that an important part of ccfDNA may originate from tumor cells. In addition, we observed that tumor-derived (mutant) ccfDNA was more fragmented than ccfDNA from normal tissues. This observation suggests that the form of tumor-derived and normal ccfDNA could differ. Our approach revealed that allelic dilution is much less pronounced than previously stated, considerably facilitating the noninvasive molecular analysis of tumors.

Citing Articles

Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection.

Bruhm D, Vulpescu N, Foda Z, Phallen J, Scharpf R, Velculescu V Nat Rev Cancer. 2025; .

PMID: 40038442 DOI: 10.1038/s41568-025-00795-x.

DNA methylation and gene expression as determinants of genome-wide cell-free DNA fragmentation.

Noe M, Mathios D, Annapragada A, Koul S, Foda Z, Medina J Nat Commun. 2024; 15(1):6690.

PMID: 39107309 PMC: 11303779. DOI: 10.1038/s41467-024-50850-8.

The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer.

Mattox A, Douville C, Wang Y, Popoli M, Ptak J, Silliman N Cancer Discov. 2023; 13(10):2166-2179.

PMID: 37565753 PMC: 10592331. DOI: 10.1158/2159-8290.CD-21-1252.

Sequence-Based Platforms for Discovering Biomarkers in Liquid Biopsy of Non-Small-Cell Lung Cancer.

Brockley L, Souza V, Forder A, Pewarchuk M, Erkan M, Telkar N Cancers (Basel). 2023; 15(8).

PMID: 37190212 PMC: 10136462. DOI: 10.3390/cancers15082275.

Comparison of the structures and topologies of plasma extracted circulating nuclear and mitochondrial cell-free DNA.

Pisareva E, Roch B, Sanchez C, Pastor B, Mirandola A, Diab-Assaf M Front Genet. 2023; 14:1104732.

PMID: 37152979 PMC: 10158822. DOI: 10.3389/fgene.2023.1104732.

References

Jung K, Fleischhacker M, Rabien A . Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. Clin Chim Acta. 2010; 411(21-22):1611-24. DOI: 10.1016/j.cca.2010.07.032. View

Morlan J, Baker J, Sinicropi D . Mutation detection by real-time PCR: a simple, robust and highly selective method. PLoS One. 2009; 4(2):e4584. PMC: 2642996. DOI: 10.1371/journal.pone.0004584. View

Holdhoff M, Schmidt K, Donehower R, Diaz Jr L . Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J Natl Cancer Inst. 2009; 101(18):1284-5. DOI: 10.1093/jnci/djp240. View

Corcoran R, Dias-Santagata D, Bergethon K, Iafrate A, Settleman J, Engelman J . BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal. 2010; 3(149):ra84. PMC: 3372405. DOI: 10.1126/scisignal.2001148. View

Mead R, Duku M, Bhandari P, Cree I . Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer. 2011; 105(2):239-45. PMC: 3142810. DOI: 10.1038/bjc.2011.230. View

Stroun M, Anker P, Maurice P, Lyautey J, LEDERREY C, Beljanski M . Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989; 46(5):318-22. DOI: 10.1159/000226740. View

Diehl F, Schmidt K, Durkee K, Moore K, Goodman S, Shuber A . Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008; 135(2):489-98. PMC: 2820386. DOI: 10.1053/j.gastro.2008.05.039. View

Soh J, Okumura N, Lockwood W, Yamamoto H, Shigematsu H, Zhang W . Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One. 2009; 4(10):e7464. PMC: 2757721. DOI: 10.1371/journal.pone.0007464. View

Rago C, Huso D, Diehl F, Karim B, Liu G, Papadopoulos N . Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res. 2007; 67(19):9364-70. DOI: 10.1158/0008-5472.CAN-07-0605. View

10.

Bustin S, Benes V, Garson J, Hellemans J, Huggett J, Kubista M . The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55(4):611-22. DOI: 10.1373/clinchem.2008.112797. View

11.

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S . Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMC: 1283450. DOI: 10.1073/pnas.0507904102. View

12.

Ellinger J, Wittkamp V, Albers P, Perabo F, Mueller S, von Ruecker A . Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J Urol. 2008; 181(1):363-71. DOI: 10.1016/j.juro.2008.08.118. View

13.

Gahan P, Stroun M . The virtosome-a novel cytosolic informative entity and intercellular messenger. Cell Biochem Funct. 2010; 28(7):529-38. DOI: 10.1002/cbf.1690. View

14.

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

15.

Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L . Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett. 2008; 263(2):170-81. DOI: 10.1016/j.canlet.2008.03.021. View

16.

Thierry A, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M . Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res. 2010; 38(18):6159-75. PMC: 2952865. DOI: 10.1093/nar/gkq421. View

17.

Schmidt K, Diehl F . A blood-based DNA test for colorectal cancer screening. Discov Med. 2007; 7(37):7-12. View

18.

Kamat A, Bischoff F, Dang D, Baldwin M, Han L, Lin Y . Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther. 2006; 5(10):1369-74. DOI: 10.4161/cbt.5.10.3240. View

19.

Mouliere F, Robert B, Peyrotte E, Del Rio M, Ychou M, Molina F . High fragmentation characterizes tumour-derived circulating DNA. PLoS One. 2011; 6(9):e23418. PMC: 3167805. DOI: 10.1371/journal.pone.0023418. View

20.

Deligezer U, Erten N, Akisik E, Dalay N . Circulating fragmented nucleosomal DNA and caspase-3 mRNA in patients with lymphoma and myeloma. Exp Mol Pathol. 2005; 80(1):72-6. DOI: 10.1016/j.yexmp.2005.05.001. View